Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis

References

• Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995 Apr;38(4):499–505.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534–2548.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Carriero A, Boccassini L, et al. Anti-IL-17 agents in the treatment of axial spondyloarthritis. Immunotargets Ther. 2021 May 3;10:141–153.
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomized, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015 Jun [Epub 2014 Feb 18];74(6):1051–1057.
   PubMed Web of Science ®Google Scholar
• Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018 Sep [Epub 2018 Jun 26];77(9):1295–1302.
   PubMed Web of Science ®Google Scholar
• Braun J, Landewé RB, No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomized controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’? Ann Rheum Dis. 2022 Apr;81(4):466–468. Epub 2021 Oct 16
   PubMed Web of Science ®Google Scholar
• Veale DJ, McGonagle D, McInnes IB, et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2019 Feb 1;58(2):197–205.
   PubMed Web of Science ®Google Scholar
• White JPE, Coates LC. JAK1 selective inhibitors for the treatment of spondyloarthropathies. Rheumatology (Oxford). 2021 May 5;60(Suppl 2):ii39–ii44.
   PubMedGoogle Scholar
• Azadeh H, Alizadeh-Navaei R, Rezaiemanesh A, et al. Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis. Inflammopharmacology. 2022 Apr [Epub 2022 Feb 21];30(2):435–451.
   PubMed Web of Science ®Google Scholar
• Kerschbaumer A, Smolen JS, Nash P, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open. 2020 Nov;6(3):e001374.
   PubMed Web of Science ®Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700–712.
   PubMed Web of Science ®Google Scholar
• Navarro-Compán V, Sepriano A, El-Zorkany B, et al. Axial spondyloarthritis. Ann Rheum Dis. 2021 Dec [Epub 2021 Oct 6];80(12):1511–1521.
   PubMed Web of Science ®Google Scholar
• Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021 Aug 12;385(7):628–639.
   PubMed Web of Science ®Google Scholar
• Braun J, Kiltz U, Baraliakos X Management of axial spondyloarthritis - insights into upadacitinib. drug design, development and therapy 2022, in press.
   Google Scholar
• Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Ther Adv Chronic Dis. 2021 Aug 12;12:20406223211037846.
   Web of Science ®Google Scholar
• Shah M, Maroof A, Gikas P, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6(2):e001306.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Wei J C-C, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomized, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018 Dec 8 [Epub 2018 Oct 22];392(10163):2441–2451.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet 2021 Feb 6; 397 (10273): 487-498. Erratum in: Lancet. 2021 Feb 20;397(10275):670.
   Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021 Jul 8 385(2):130–141.
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021 Jul 8;385(2):142–152. Epub 2021 Apr 23
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020 Feb 8 395(10222):427–440.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Gensler LS, Deodhar A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomized, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis 2020 May; 79(5):595-604. Epub 2020 Apr 6. Erratum in: ann Rheum Dis 2020 Sep; 79 (9):e121. Erratum in: Ann Rheum Dis. 2021 Nov; 80(1) e186
   PubMedGoogle Scholar
• Baraliakos X, Deodhar A, Dougados M, et al. Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 3-year results from a phase 2b randomized controlled trial and its open-Label extension study. Arthritis Rheumatol. 2022 Jul 13; Epub ahead of print. 10.1002/art.42282.
   Google Scholar
• van der Heijde D, Baraliakos X, Dougados M, et al. EULAR 2022: OP0019. Bimekizumab in patients with active ankylosing spondylitis: 24-week efficacy and safety data from BE MOBILE 2, a phase 3, multicentre, randomized, placebo-controlled study. Ann Rheum Dis. 2022;81(Suppl 1):12–13.
   Google Scholar
• Deodhar A, van der Heijde D, Gensler LS, et al. EULAR 2022: POS0939. Bimekizumab in patients with active non-radiographic axial spondyloarthritis: 24-week efficacy and safety data from BE MOBILE 1, a phase 3, multicentre, randomized, placebo-controlled study. Ann Rheum Dis. 2022;81(Suppl 1):772–773.
   Google Scholar
• Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014 Jan;73(1):39–47.
   PubMed Web of Science ®Google Scholar
• Erdes S, Nasonov E, Kunder E, et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol. 2020 Jan-Feb [Epub 2019 Apr 16];38(1):27–34.
   PubMed Web of Science ®Google Scholar
• Papp KA, Weinberg MA, Morris A, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomized, placebo-controlled, phase 2b study. Lancet. 2021 Apr 24; 397(10284):1564-1575. Erratum in: Lancet. 2021 Jun 5;397(10290):2150.
   Web of Science ®Google Scholar
• Behrens F, Taylor PC, Wetzel D, et al. OP0258 at EULAR 2022. Izokibep (ABY-035) in patients with active psoriatic arthritis – 16-week results from a phase 2 study. Ann Rheum Dis. 2022;81(Suppl 1):170–171.
   Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014 Jun 12 370(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2022 Jul 9;S0190-9622(22):02256. Epub ahead of print.
   Google Scholar
• van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomized, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017 Aug [Epub 2017 Jan 27];76(8):1340–1347.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomized, double-blind, placebo-controlled study. Ann Rheum Dis. 2021 Aug [Epub 2021 Apr 27];80(8):1004–1013.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomized, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022 Jul;4:annrheumdis-2022–222608. Epub ahead of print
   Google Scholar
• Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022 Jul 30 400(10349):369–379.
   PubMedGoogle Scholar
• van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomized, placebo-controlled, phase 2 trial. Lancet. 2018 Dec 1;392(10162):2378–2387. Epub 2018 Oct 22.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016 Mar 31 374(13):1243–1252.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022 Jan 27 386(4):316–326.
   PubMed Web of Science ®Google Scholar
• Simon D, Fagni F, Schett G, Sequential interleukin-17/interleukin-23 inhibition in treatment-refractory psoriatic arthritis. Ann Rheum Dis. 2022 May 5;annrheumdis-2022–222415.
   Web of Science ®Google Scholar
• https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx
   Google Scholar
• https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca
   Google Scholar
• Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomized, placebo-controlled, phase 2 trial. Lancet. 2018 Dec 1 392(10162):2367–2377.
   PubMed Web of Science ®Google Scholar
• Nash P. Janus kinase inhibitors: safety in patients with psoriatic arthritis. J Rheumatol. 2022 Jun;49(6 Suppl 1):44–47. Epub 2022 Mar 15.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Popa CD, Nucera V, et al. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. Expert Rev Clin Immunol. 2022 Mar [Epub 2022 Feb 17];18(3):233–244.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Tanaka Y, Takeuchi T, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis. 2022 Feb [Epub 2021 Nov 5];81(2):184–192.
   PubMed Web of Science ®Google Scholar
• Hellstrom W, Dolhain R, Ritter T, et al. MANTA and MANTA-RAy: rationale and design of trials evaluating effects of filgotinib on semen parameters in patients with inflammatory diseases. Adv Ther. 2022;39(7):3403–3422.
   PubMed Web of Science ®Google Scholar
• https://www.globenewswire.com/en/news-release/2021/03/04/2186756/0/en/GALAPAGOS-REPORTS-PRIMARY-ENDPOINT-FOR-THE-ONGOING-FILGOTINIB-MANTA-AND-MANTA-RAy-SAFETY-STUDIES.html
   Google Scholar
• Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014 Jan [Epub 2013 Sep 26];73(1):3–5.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Buehring B, et al. Imaging of axial spondyloarthritis. New aspects and differential diagnoses. Clin Exp Rheumatol. 2018 Sep-Oct; 36 114(5):35–42.
   Google Scholar
• Braun J, Fruth M, Baraliakos X. What’s new on the sacroiliac joint ? Rheumatology (Oxford). 2022 Feb 2; 61(2):475–477.
   PubMedGoogle Scholar
• Baraliakos X, Ghadir A, Fruth M, et al. Which magnetic resonance imaging lesions in the sacroiliac joints are most relevant for diagnosing axial spondyloarthritis? A prospective study comparing rheumatologists’ evaluations with radiologists’ findings. Arthritis Rheumatol. 2021 May [Epub 2021 Mar 24];73(5):800–805.
   PubMedGoogle Scholar
• Dougados M, Maksymowych WP, Landewé RBM, et al. Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis. Ann Rheum Dis. 2018 Feb [Epub 2017 Sep 29];77(2):221–227.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Østergaard M, Landewé R, et al. Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial. Rheumatology (Oxford) 2022 May 30; 61(6): 2388–2397.
   Google Scholar
• Maksymowych WP, Baraliakos X, Lambert RG, et al. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis. Lancet Rheumatol. 2022;4(9):e626–e634.
   Google Scholar
• Torgutalp M, Rios Rodriguez V, Proft F, et al. Treatment with tumor necrosis factor inhibitors is associated with a time-shifted retardation of radiographic sacroiliitis progression. in patients with axial spondyloarthritis: 10-year results from the German spondyloarthritis inception cohort. Arthritis Rheumatol. 2022 Sep;74(9):1515-1523.
   Google Scholar
• Braun J, Kiltz U, Baraliakos X, Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning. Ann Rheum Dis. 2022 Jan;81(1):11–14. Epub 2021 Oct 28
   PubMed Web of Science ®Google Scholar
• Braun J. Significance of structural changes in the axial skeleton in patients with axial spondyloarthritis: how important are lesions in the sacroiliac joint? RMD Open. 2022 Dec;8(2):e002822.
   Web of Science ®Google Scholar
• Torgutalp M, Rios Rodriguez V, Dilbaryan A, et al. Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis. 2022 Jun 13;81(9):1252–9.
   Google Scholar
• Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022Jun; 81(6): 815–822. Epub 2022 Mar 3.
   PubMed Web of Science ®Google Scholar